PF-4800567

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H18ClN5O2
Molecular Weight	359.81
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC=NC2=C1C(COC3=CC=CC(Cl)=C3)=NN2C4CCOCC4

InChI

InChIKey=AUMDBEHGJRZSOO-UHFFFAOYSA-N

InChI=1S/C17H18ClN5O2/c18-11-2-1-3-13(8-11)25-9-14-15-16(19)20-10-21-17(15)23(22-14)12-4-6-24-7-5-12/h1-3,8,10,12H,4-7,9H2,(H2,19,20,21)

HIDE SMILES / InChI

Molecular Formula	C17H18ClN5O2
Molecular Weight	359.81
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19458106 | https://www.ncbi.nlm.nih.gov/pubmed/20696890 | https://www.ncbi.nlm.nih.gov/pubmed/22089318 | https://www.ncbi.nlm.nih.gov/pubmed/27605609

PF 4800567 is a drug developed by Pfizer which acts as a selective potent inhibitor of CK1epsilon (IC(50) = 32 nM) with greater than 20-fold selectivity over CK1delta, and has mainly been used in the study of the casein kinase 1 enzymes in the regulation of circadian rhythm, as well as showing potential neuroprotective effects. PF 4800567 was found in animal studies to enhance responses to certain drugs of abuse such as methamphetamine and fentanyl, which suggests a role for CK1-ε in negative regulation of sensitivity to stimulant and opioid drugs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Casein kinase I epsilon 5 Target ID: CHEMBL4937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19458106	Inhibitor 8504		32.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2596

PubMed

Title	Date	PubMed
Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioids.	2012-03	22089318
IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation.	2011-06-02	21258417
Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes.	2010-08-24	20696890
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period.	2009-08	19458106

Patents

Sample Use Guides

In Vivo Use Guide

Mice: 40 mg/kg, i.p.

Route of Administration: Intraperitoneal

In Vitro Use Guide

A significant lengthening of the period was observed at 1 uM PF 4800567 (approximately 10-fold CK1ε IC50; approximately 0.5- fold CK1δ IC50) in WT (0.9 ± 0.13 h increase in period) but not Ck1ε −/− -derived primary lung fibroblast cells (0.3 ± 0.3 h).

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:20:10 GMT 2025` Edited by `admin` on `Wed Apr 02 09:20:10 GMT 2025`
Record UNII	GEE72DRC63
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PF-4800567

Code

English

PF4800567

Preferred Name

English

1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[(3-chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-

Systematic Name

English

3-[(3-Chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Systematic Name

English

Code System Code Type Description

CAS

1188296-52-7